4.7 Article

Long-Term Follow-Up after Adoptive Transfer of BK-Virus-Specific T Cells in Hematopoietic Stem Cell Transplant Recipients

Related references

Note: Only part of the references are listed.
Article Oncology

Posoleucel, an Allogeneic, Off-the-Shelf Multivirus-Specific T-Cell Therapy, for the Treatment of Refractory Viral Infections in the Post-HCT Setting

Thomas Pfeiffer et al.

Summary: This study aimed to evaluate the feasibility and safety of posoleucel in allo-HCT recipients infected with viral infections. The results showed that posoleucel had good tolerability and achieved significant efficacy in treating multiple viral infections.

CLINICAL CANCER RESEARCH (2023)

Article Biotechnology & Applied Microbiology

Rapid Manufacturing of Highly Cytotoxic Clinical-Grade SARS-CoV-2-specific T Cell Products Covering SARS-CoV-2 and Its Variants for Adoptive T Cell Therapy

Agnes Bonifacius et al.

Summary: This study evaluated the feasibility of using SARS-CoV-2-specific T cell manufacturing for adoptive T cell transfer in COVID-19 patients at risk for severe disease. The researchers successfully detected antiviral SARS-CoV-2-specific T cells in the blood of convalescent COVID-19 patients and generated clinical-grade T cell products with good functionality and target-specific cytotoxic potential. These T cells remained stable and functional for several days after enrichment. The findings suggest that the adoptive transfer of partially matched, viable SARS-CoV-2-specific T lymphocytes collected from convalescent individuals could be a potential strategy to support the immune system of severe COVID-19 patients.

FRONTIERS IN BIOENGINEERING AND BIOTECHNOLOGY (2022)

Article Immunology

Prospective, Longitudinal Study on Specific Cellular Immune Responses after Vaccination with an Adjuvanted, Recombinant Zoster Vaccine in Kidney Transplant Recipients

Monika Lindemann et al.

Summary: Solid organ transplant recipients have a higher risk of VZV reactivation, and vaccinating them with the adjuvanted, recombinant zoster vaccine Shingrix significantly enhances their cellular immunity against VZV.

VACCINES (2022)

Article Biophysics

Incidence, risk factors and outcome of BK virus hemorrhagic cystitis following allogenic hematopoietic cell transplantation: a retrospective cohort study

Anastasia Saade et al.

Summary: BK polyomavirus can cause hemorrhagic cystitis after allogeneic hematopoietic cell transplantation. Competitive risk analysis showed a high incidence of BKHC, but it did not affect overall mortality. Myeloablative conditioning regimen and CMV seropositivity were associated with BKHC.

BONE MARROW TRANSPLANTATION (2022)

Article Immunology

BK Polyomavirus Specific CD8 T-Cell Expansion In Vitro Using 27mer Peptide Antigens for Developing Adoptive T-Cell Transfer and Vaccination

Maud Wilhelm et al.

Summary: Using synthetic 27mer-long BKPyV peptides, different types of antigen-presenting cells, and CD4 T cells, BKPyV-specific CD8 T cell responses were expanded, providing a novel approach for vaccination and adoptive T-cell therapies for patients before and after kidney transplantation.

JOURNAL OF INFECTIOUS DISEASES (2021)

Article Immunology

Case Report: Fatal Complications of BK Virus-Hemorrhagic Cystitis and Severe Cytokine Release Syndrome Following BK Virus-Specific T-Cells

Elizabeth M. Holland et al.

Summary: This case report describes a 16-year-old male with DOCK8 deficiency who underwent haploidentical HSCT and developed severe BKV-associated hemorrhagic cystitis, renal hemorrhage, and VST-associated cytokine release syndrome. The case highlights opportunities for improvement in managing severe BKV-HC post-transplant and underscores rare and potentially life-threatening complications of VST therapy.

FRONTIERS IN IMMUNOLOGY (2021)

Article Oncology

Third-Party BK Virus-Specific Cytotoxic T Lymphocyte Therapy for Hemorrhagic Cystitis Following Allotransplantation

Amanda Olson et al.

Summary: The study shows that treatment with BKV-specific CTLs is safe and effective for managing patients with BKV-HC after AHSCT. The response rate is rapid, with overall response rates of 67.7% at day 14 and 81.6% at day 45. Compared to standard care, treatment with BKV-CTLs results in higher response probabilities and lower transfusion requirements.

JOURNAL OF CLINICAL ONCOLOGY (2021)

Article Immunology

The Natural History of BK Polyomavirus and the Host Immune Response After Stem Cell Transplantation

Benjamin L. Laskin et al.

CLINICAL INFECTIOUS DISEASES (2020)

Review Infectious Diseases

BK polyomavirus-specific antibody and T-cell responses in kidney transplantation: update

Amandeep Kaur et al.

CURRENT OPINION IN INFECTIOUS DISEASES (2019)

Article Medicine, Research & Experimental

Toward a Rapid Production of Multivirus-Specific T Cells Targeting BKV, Adenovirus, CMV, and EBV from Umbilical Cord Blood

Hema Dave et al.

MOLECULAR THERAPY-METHODS & CLINICAL DEVELOPMENT (2017)

Review Microbiology

BK Polyomavirus: Clinical Aspects, Immune Regulation, and Emerging Therapies

George R. Ambalathingal et al.

CLINICAL MICROBIOLOGY REVIEWS (2017)

Review Urology & Nephrology

BK and Other Polyomaviruses in Kidney Transplantation

Jennifer Trofe-Clark et al.

SEMINARS IN NEPHROLOGY (2016)

Article Immunology

Prevalence of Polyomavirus BK and JC Infection and Replication in 400 Healthy Blood Donors

Adrian Egli et al.

JOURNAL OF INFECTIOUS DISEASES (2009)

Review Transplantation

Cellular immune responses to BK virus

Patrizia Comoli et al.

CURRENT OPINION IN ORGAN TRANSPLANTATION (2008)